Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

2.050 -0.100 (-4.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 277,347
Open 2.140
Bid (Size) 2.000 (12)
Ask (Size) 2.090 (5)
Prev. Close 2.150
Today's Range 2.011 - 2.140
52wk Range 1.570 - 35.25
Shares Outstanding 171,350,166
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Via ACCESS Newswire
Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition
Via ACCESS Newswire

Performance

YTD
-92.5%
-92.5%
1 Month
+14.5%
+14.5%
3 Month
-29.8%
-29.8%
6 Month
-60.0%
-60.0%
1 Year
-92.5%
-92.5%

More News

Read More
Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts
Via ACCESS Newswire
Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts
Via ACCESS Newswire
Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs
Via ACCESS Newswire
Earnings Scheduled For August 14, 2025
Via Benzinga
Earnings Preview For Jaguar Health
Via Benzinga
Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders
Via ACCESS Newswire
Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)
Via ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue
Via ACCESS Newswire
Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates
Via ACCESS Newswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Via ACCESS Newswire
Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS
Via ACCESS Newswire
Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient
Via ACCESS Newswire
Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset
Via Stocktwits
Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset
Via ACCESS Newswire
Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs
Via ACCESS Newswire
Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026
Via ACCESS Newswire
Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer
Via ACCESS Newswire
Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
Via ACCESS Newswire
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Via ACCESS Newswire
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series
Via ACCESS Newswire
Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer
Via ACCESS Newswire

Frequently Asked Questions

Is Jaguar Health, Inc. - Common Stock publicly traded?
Yes, Jaguar Health, Inc. - Common Stock is publicly traded.
What exchange does Jaguar Health, Inc. - Common Stock trade on?
Jaguar Health, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Jaguar Health, Inc. - Common Stock?
The ticker symbol for Jaguar Health, Inc. - Common Stock is JAGX on the Nasdaq Stock Market
What is the current price of Jaguar Health, Inc. - Common Stock?
The current price of Jaguar Health, Inc. - Common Stock is 2.050
When was Jaguar Health, Inc. - Common Stock last traded?
The last trade of Jaguar Health, Inc. - Common Stock was at 09/25/25 04:00 PM ET
What is the market capitalization of Jaguar Health, Inc. - Common Stock?
The market capitalization of Jaguar Health, Inc. - Common Stock is 351.27M
How many shares of Jaguar Health, Inc. - Common Stock are outstanding?
Jaguar Health, Inc. - Common Stock has 351M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.